Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Morgan Stanley Adjusts Price Target on Merck & Company to $88 From $85, Maintains Equal-Weight Rating

10/12/2021 | 09:43am EST


ę MT Newswires 2021
All news about MERCK & CO., INC.
12/03FDA Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Treatment for Adult and Pedi..
BU
12/03Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19
DJ
12/03Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupira..
AQ
12/03Canada Signs Deal for 1 Mln Doses of Pfizer Covid Antiviral and 500K Merck's Covid Pill
MT
12/03Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
12/03Bristol-Myers Squibb's Supplemental Biologics License Application for Drug Co-Developed..
MT
12/03KYODO NEWS DIGEST : Dec. 3, 2021 -3-
AQ
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/03Nikkei 225 Gains 1% on Merck Covid-19 Drug Application
MT
12/03U.S. pharma Merck unit seeks Japan's approval of oral COVID drug
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 572 M - -
Net income 2021 12 378 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 15,1x
Yield 2021 3,54%
Capitalization 185 B 185 B -
EV / Sales 2021 4,24x
EV / Sales 2022 3,55x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,34 $
Average target price 95,25 $
Spread / Average Target 29,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.34%185 253
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641